Breaks Categories: News

TuesdaySep 24, 2024 2:55 pm

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Featured at Next Month’s NYC ThinkEquity Conference

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, will be presenting at the ThinkEquity Conference held on Oct. 30, 2024, in New York City. According to the announcement, TC Biopharm CEO Bryan Kobel will be presenting at the conference. During his presentation, Kobel will provide an overview of the company's clinical trials along with recent improvements to TC BioPharm's balance sheet. Hosted by ThinkEquity, a boutique investment bank, the ThinkEquity Conference is a premier showcase of private and public emerging growth companies from all over the world. To view the…

Continue Reading

TuesdaySep 24, 2024 12:29 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Industry Expert, Pioneer as New Chief AI Scientist

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, has appointed a new chief artificial intelligence (“AI”) scientist: Lance Myers, PhD. According to the announcement, Myers is the former head of data science at Verily, formerly Google Life Sciences. A renowned industry leader and pioneer in digital health data analytics and body-worn biosensor technologies, Myers is a globally respected authority on utilizing AI in biosensor tech. In his new position, Myers will drive innovation and strategic growth for HeartBeam as the company looks to fully leverage its AI…

Continue Reading

TuesdaySep 24, 2024 10:00 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more. To view the full press release, visit https://ibn.fm/3khUt About Nutriband Inc.…

Continue Reading

MondaySep 23, 2024 11:20 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the full press release, visit https://ibn.fm/P0zd8 About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing…

Continue Reading

FridaySep 20, 2024 12:45 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product

Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, AVERSA(TM) Fentanyl, an abuse deterrent fentanyl patch. The company’s abuse-deterrent transdermal technology includes the utilization of a proprietary aversive agent coating that uses taste aversion as a means to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. According…

Continue Reading

ThursdaySep 19, 2024 11:25 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has been awarded a patent by the United States Patent and Trademark Office; the patent is titled “Formulations Comprising Triptan Compounds.” According to the announcement, the patent was issued on Sept. 17, 2024, and is slated to expire in 2030. The company noted that the patent claims a pharmaceutical composition, a method of treating migraine via intranasal administration and an intranasal delivery system for Tosymra(R). “We believe this patent further solidifies Tosymrain the market as a differentiated drug with a differentiated administration…

Continue Reading

ThursdaySep 19, 2024 11:10 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Announces Expansion of Its Telehealth Services Nationwide, New Service

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced a partnership with Lyric Health, a comprehensive virtual care provider. This partnership, which entails integrating HealthLynked with Lyric Health, enables the company to expand its telehealth services nationwide to all 50 states. As part of this expansion, the company has introduced its new Virtual Urgent Care service, which enables members to connect with a licensed physician within an average of 20 minutes. Additionally, HealthLynked intends to launch its Virtual Primary Care service, which will allow users to set future appointments with primary care physicians, establishing ongoing relationships with virtual doctors.…

Continue Reading

WednesdaySep 18, 2024 10:13 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) TNX-801 Positioned as Viable Contender in Global Fight Against Mpox

Tonix Pharmaceuticals Holding (NASDAQ: TNXP) is a biopharmaceutical company with marketed products and a pipeline of development candidates. Tonix’s TNX-801, a live-virus vaccine candidate, could potentially offer a more viable solution to address the growing global mpox crisis. TNX-801 shows promise because it appears to align with the preferred target product profile (“TPP”) recently issued by the World Health Organization (“WHO”). The TPP emphasizes a well-tolerated, single-dose vaccine that can be administered, shipped and stored in Africa and around the world. Jynneos(R) and ACAM2000(R), two FDA-approved vaccines for mpox, do not fully meet WHO’s TPP. Thus, TNX-801 potentially offers a…

Continue Reading

TuesdaySep 17, 2024 8:55 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports on Share Repurchase Program

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has authorized a share repurchase program to buy back up to $1 million of its common stock. According to the announcement, as of Sept. 16, 2024, the company had 11,106,185 shares of common stock outstanding. The company also reported that it is continuing to make progress on the development of AVERSA Fentanyl, with a target date of submitting a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2025. To view the full press release, visit https://ibn.fm/AfJJt About Nutriband Inc. Nutriband is primarily…

Continue Reading

MondaySep 16, 2024 10:56 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, will be meeting in-person with the U.S. Food and Drug Administration (“FDA”) before the end of November 2024. The company announced that the meeting, which will focus on discussions about the development of the company’s proprietary CNM-Au8 for the treatment of amyotrophic lateral sclerosis (“ALS”), will include key FDA representatives, including the organization’s director of the Office on New Drugs and director of the Office of Neuroscience, as well as the Division of Neurology 1 (“DN1”) review team and key…

Continue Reading